glp 1 studies 2025 A network meta-analysis backed weight-loss benefits with several GLP-1 receptor agonists, with less certainty for newer-generation agents. Read more at the link in bio Glucagon-Like Peptide-1 and Hypothalamic Regulation

A review published in 2025 in the Journal of Crohns and Colitis suggests that GLP-1 medications have both metabolic and anti-inflammatory benefits for people with IBD, with early studies linking them to improved outcomes like fewer hospitalizations

p = 0.019)

22 However, the fact that the magnitude and speed of hemoglobin A1c reduction with treatment were identified as risk factors for progression suggests it could be another example of the well-established early worsening phenomenon first observed in type 1 diabetic patients intensively treated with insulin in the Oslo Study, Kroc Collaborative Study and Diabetes Control and Complications Trial

doi:10.1016/j.neuroscience.2012.09.025 76

In a mouse model of osteoarthritis induced by destabilization of the medial meniscus, glycoursodeoxycholic acid was found to mitigate disease progression, an effect associated with an increase in intestinal L cell numbers (87)